Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$31.62B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Fresenius SE & Co. KGaAFresenius SE & Co. KGaA19.21.96%8%1.30.6

Earnings Call Q3 2026

November 4, 2026 - AI Summary

Strong Q3 performance + guidance upgrade (core EPS & margins): - Fresenius delivered “another excellent quarter” with 5% organic revenue growth and double-digit core EPS growth of +14% at constant currency (also +14% year-to-date). - Group EBIT margin increased +50 bps YoY to 11%; for the full year Fresenius raised the group margin indication to “above 11.5%”. - Core EPS outlook improved: now expects upper half of 10%–15% core EPS growth at constant currency (i.e., stronger than prior guidance). - Q4 phasing: at Helios, Germany public-patient surcharge expired end of Oct, so Q4 has 1 month benefit vs 2 months in prior-year quarter; Spain faces a tough comparison after strong Q4 2025 settlements.
Cash generation and balance sheet strength despite transaction cash out: - Free cash flow (last 12 months) more than doubled YoY to EUR 1.9bn (includes ~EUR 640m from FME proceeds; noted FME proceeds and cash conversion context). - Leverage remained ~2.5x despite cash out for the remaining stake in mAbxience, supported by operating cash flow and FME share sale. - Management expects interest expense below EUR 300m for full year, reflecting lower debt and refinancing on improved terms (noted early refinancing of EUR 2bn revolving credit facility). - FX sensitivity assumption: if exchange rates stay at 30 Sept spot, they expect no material impact on full-year reported revenue/EBIT/net income.
Fresenius Kabi: growth vectors accelerating; biopharma is the key engine; MedTech expanding installed base: - Kabi delivered ~6% organic revenue growth (upper half of structural growth band), aligned with phasing. - Growth vectors grew +9%, and biopharma led with +29% organic growth (Tyenne momentum plus denosumab demand, highlighting diversification). - MedTech: Ivenix infusion system rollout in the US accelerating; installed base >30,000 units and a new multi-hospital Arizona contract increased demand visibility; future revenue increasingly recurring via installed base and bundled offerings. - Nutrition: growth affected by temporary constraints in China supply/procurement; improved trajectory expected in Q4.

Exclusive for Stockcircle Pro members

Sign upSign Up
$27.73

Current Fair Value

50.9% downside

Overvalued by 50.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$31.62 Billion
Enterprise Value$41.93 Billion
Annual dividend$1.22
Dividend yield1.96%
Earnings per Share$2.25
Beta0.83
Outstanding Shares559,722,000

Return

Return on Equity7.75%ROE
Return on Assets3.76%
Return on Invested Capital7.12%

Valuation & Multiples

P/E Ratio19.15P/E Ratio
PEG114.5PEG
Price to Sales1.35Price to Sales
Price to Book Ratio1.53Price to Book Ratio
Enterprise Value to Revenue1.76
Enterprise Value to EBIT17.24
Enterprise Value to Net Income26
Total Debt to Enterprise0.29
Debt to Equity0.59Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 4, 2026
EPS
$0.82
Est. $0.88
Revenue
$6.57 B
Est. $6.56 B

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
$1.03
Consensus analyst estimate
Revenue Estimate
$6.86 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Fresenius SE & Co. KGaA

178,486 employees
CEO: Michael Sen

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured ...